Matthew Kurian, Executive Committee Member at KYSCO, shared on LinkedIn:
“5 years is a long time – tolerability matters.
ESMO26 Honorable Mention: lidERA PROs.
If giredestrant becomes our first adjuvant oral SERD, what will 5 years of therapy actually feel like for patients?
We’ve seen less arthralgia and fewer discontinuations vs standard endocrine therapy. Now I want to see the broader picture: hot flashes, sexual health, fatigue, sleep, quality of life – and whether any advantages persist over time.
For adjuvant endocrine therapy, how patients feel may shape how long they stay on treatment.”
You can also read:
lidERA Trial at SABCS 2025: Giredestrant in ER+/HER2− Early Breast Cancer
